Company Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.
The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults.
Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders.
In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders.
The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011.
Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 353 |
| CEO | Barry Greene |
Contact Details
Address: 55 Cambridge Parkway Cambridge, Massachusetts 02142 United States | |
| Phone | 617 299 8380 |
| Website | sagerx.com |
Stock Details
| Ticker Symbol | SAGE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001597553 |
| CUSIP Number | 78667J108 |
| ISIN Number | US78667J1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Barry E. Greene | President, Chief Executive Officer and Director |
| Christopher Benecchi | Chief Operating Officer |
| Mike Quirk Ph.D. | Chief Scientific Officer |
| Ashley Kaplowitz | Director of Investor Relations |
| Gregory Shiferman | Senior Vice President and General Counsel |
| Pamela Herbster | Vice President and Head of People |
| Dr. Helen Colquhoun | Senior Vice President of Drug Safety and Pharmacovigilance |
| Vanessa Procter | Senior Vice President of Corporate Affairs |
| Dr. Aaron Koenig M.D. | Medical Director of Early Clinical Development |
| Maren Killackey | Senior Analyst of Investor Relation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 7, 2025 | SCHEDULE 13G/A | Filing |
| Mar 6, 2025 | SCHEDULE 13G/A | Filing |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | POS AM | Post-Effective amendments for registration statement |
| Feb 11, 2025 | 10-K | Annual Report |
| Feb 11, 2025 | 8-K | Current Report |
| Feb 11, 2025 | POSASR | Filing |
| Feb 5, 2025 | SCHEDULE 13G | Filing |